The British University in Egypt

BUE Scholar
Pharmacy

Health Sciences

2009

In Vitro and in Vivo Evaluation of Transdermal Absorption of
Naproxen Sodium
Dalia Attia
dalia.rhman@bue.edu.eg

Follow this and additional works at: https://buescholar.bue.edu.eg/pharmacy

Recommended Citation
Attia, Dalia, "In Vitro and in Vivo Evaluation of Transdermal Absorption of Naproxen Sodium" (2009).
Pharmacy. 537.
https://buescholar.bue.edu.eg/pharmacy/537

This Article is brought to you for free and open access by the Health Sciences at BUE Scholar. It has been accepted
for inclusion in Pharmacy by an authorized administrator of BUE Scholar. For more information, please contact
bue.scholar@gmail.com.

Australian Journal of Basic and Applied Sciences, 3(3): 2154-2165, 2009
ISSN 1991-8178

In Vitro and in Vivo Evaluation of Transdermal Absorption of Naproxen Sodium
Dalia A. Attia
Pharmaceutics Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
Abstract: Naproxen sodium is a non steroidal antiinflammatory drug, used in the treatment of
inflammatory and degenerative disorders of the musculoskeletal system. It is widely prescribed for the
treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, extra-articular disorders,
bursitis, tendonitis, and non articular rheumatic condition. Naproxen sodium has some side effects
when taken orally, epigastric pain, heartburn, nausea, diarrhoea, vomiting, peptic ulcer, and hepatic
impairment. The aim of this study was to formulate topical gel containing 1% of naproxen sodium
using various ratios of different type of gel forming agents as pectin, hydroxypropylmethyl cellulose
low and high viscosity (HPlv&hv), carboxymethyl cellulose (CMC), and carbopol 934 with and
without penetration enhancers; isopropyl myristate (IPM) and sodium lauryl sulphate (NaLS). Also the
duration of anti-inflammatory activity of new gel formulation of 1% naproxen sodium was measured
using carrageenan-induced paw oedema in rats. Furthermore, the pharmacokinetics percutaneous
absorption of 1% naproxen sodium from three different gel formulations prepared with pectin, HPlv
and carbopol as gel forming agent without penetration enhancers, was studied in six healthy human
volunteers. W hile orally administered naproxen sodium tablet (marketed as Naprofen®) was used as
a control. Bioavailability was estimated from plasma concentration which determined up to 72 hr after
drug administration. The drug plasma concentration was higher from pectin gel (15.944μg.hr/ml)
followed by HPlv (14.4199μg.hr/ml) then carbopol (8.5781μg.hr/ml) with the corresponding rate of
drug elimination (Kel) of 0.085 hr -1 , 0.13hr -1 and 0.11hr -1 respectively. The PK parameters, such as the
maximum blood concentration (C m ax ), time to reach the peak blood concentration (T m ax ), mean
residence time (MRT), area under the curve (AUC 0 –4 ) and terminal elimination half-life (t1 /2 ) were
significantly (p <0.001) different following transdermal administration of 1% naproxen sodium gel
prepared with pectin without penetration enhancers compared with oral administration of reference
naproxen sodium tablet Naprofen®.
Key words: In vitro, in vivo, transdermal absorption, naproxen sodium.
INTRODUCTION
The transdermal route has many advantages for the administration of drugs for local and systemic therapy.
Recent development in transdermal drug delivery systems have been extensively studied as drug delivery
methods showing promising systemic and topical efficacy (Okamoto et al., 1986; Hadgraft and Ridout 1988;
Potts and Francoeur 1990; Yamada and Uda 1987) the outermost layer of skin, the stratum corneum (SC),
forms a strong barrier to most exogenous substances including drugs. The barrier function of the SC is
attributed to its multilayered wall-like structure, in which terminally differentiated keratin-rich epidermal cells
(corneocytes) are embedded in an intercellular lipid-rich matrix (Hui, et al., 2005) .One approach to deliver
an effective dose of drug through skin is to reversibly reduce the barrier function of skin with the aid of
penetration enhancers or accelerants (Hadgraft, et al. 1999). The therapeutic efficacy of a drug, following its
application onto the skin, mainly depends on its ability to penetrate the skin at such extent to elicit the desired
pharmacological activity. Since most drugs show unsuitable physicochemical properties to penetrate effectively
the skin different strategies have been developed to increase drug skin permeation. Penetration enhancers have
been extensively used to increase drug percutaneous absorption the prodrug should exhibit an adequate aqueous
stability (Valenta et al., 2000; Finnin and M organ, 1999; Godwin and Michniak, 1999) although they show
some disadvantages (Hadgraft, 1989) The treatment of skin diseases as well as of musculoskeletal disorders
might benefit from topical administration, obtaining a substantial reduction of the systemic side effects and an
improvement of the patient compliance. Drug topical administration is still a challenge in pharmaceutics and
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drug delivery due to the difficulties in controlling and, not less important, determining the exact amount of
drug that reach the different skin layers (Schoafer-Korting et al., 2007).The active ingredient as well as the
vehicle physicochemical characteristics are retained to be the main features responsible for the drug differential
distribution in the skin (Beetge et al., 2000; Jacobi et al., 2006; Teichmann et al., 2007).
The NSAIDs has prominent anti-inflammatory, analgesic and antipyretic properties. Oral therapy of
NSAIDs is very effective, but the clinical use is often limited because of their potential to cause adverse
effects such as irritation and ulceration of the gastro-intestinal (GI) mucosa. It has been reported that gastric
irritation induced by NSAIDs can be influenced by the route of administration (Cioli et al., 1979).
Administration of these agents via the dermal route can bypass these disadvantages of the oral route and may
maintain relatively consistent plasma levels for long term therapy from a single dose (Berba et al., 1991).
Naproxen sodium [(S)-6-methoxy-alpha-methyl-2naphthaleneacetic acid sodium salt] is an NSAID with
analgesic and antipyretic properties (Sevelius et al., 1980; Capone et al., 2007; Moyer 1986; Segre 1980) used
for the treatment of musculoskeletal disorders (e.g., rheumatoid arthritis, osteoarthritis and ankylosing
spondylitis) with non-optimal characteristics to be delivered through the skin (Swart et al., 2005). The
mechanism of action of the naproxen anion, like that of other NSAIDs, is primarily due to the inhibition of
prostaglandin biosynthesis through the inhibition of the cyclooxygenase (COX) enzymes COX-l and COX-2
(Capone et al., 2007).
Different strategies have been used to increase local soft tissue bioavailability of naproxen topically
administered (Rautio et al., 1998; Bonina et al., 2001). In order to increase therapeutic efficacy after topical
application of drugs, it is necessary to employ percutanous absorption enhancer and /or appropriate vehicles.
An attempt has been made, to enhance the transdermal permeation of naproxen sodium by using different types
of gel forming agents as delivery vehicles.
The present study aims to evaluate the efficacy of naproxen sodium gel formulations prepared with five
different gel forming agents as pectin, CMC, HPhv, HPlv and carbopol with and without penetration enhancers
(isopropyl myristate (IPM) and sodium lauryl sulphate NaLS) for transdermal delivery of naproxen sodium
across the rat skin in vitro, and to determine whether therapeutically relevant delivery rates could be achieved
under these conditions when applied transdermally in vivo on healthy volunteers.
M ATERIALS AND M ETHODS
Materials:
Naproxen sodium powder and pectin were obtained as gift sample from El-Nile Pharmaceutical Chemical
Company, Cairo, Egypt. Hydroxpropyl methyl cellulose powder high and low viscosities 15000, 4000
respectively, were purchased from Sigma Chemical Co. (USA). Carboxymethyl cellulose and Carbopol 934
were kindly supplied by Egyptian International Pharmaceutical Industries Company (E.I.P.I.Co), Egypt. All
other chemicals were commercially available products of analytical grade.
Preparation of Naproxen Gel Formulations:
Various gel formulations are listed in Table (1). To each of the following gel bases, the naproxen sodium
is added at 1%w/w concentration and also the different ratios of penetration enhancers were added by mean
of gentle levigation.
Preparation of Carboxym ethyl Cellulose (CMC) Gels:
The weighed amount of CMC powder were sprinkled gently in 100 ml beakers, containing boiling
dist.water and stirred magnetically at a high speed ( D ubuque Lowa USA), stirring was continued until a thin
hazy dispersion, without lumps, were formed. Leaving the gel overnight in the refrigerator (Pharmaceutical
exipients, 2003).
Preparation of Hydroxypropylm ethyl cellulose (HPMC) Gels:
The weighed amount of HPMC powder, both viscosity, were sprinkled gently in 100 ml beakers,
containing a portion of hot water at 80°C and stirred magnetically at high speed (Dubuque Lowa USA).
Stirring was continued until a thin hazy dispersion, without lumps, was formed the remaining amount of water
was added on cold and mixing was continued till smooth homogenous gel is formed. Leaving the gel overnight
in the refrigerator (Pharmaceutical exipients, 2003).
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Preparation of Pectin Gels:
The weighed amount of pectin powder were sprinkled gently in 100 ml beakers containing a portion of
warm water and stirred magnetically at high speed (Dubuque Lowa USA). Stirring was continued until a thin
hazy dispersion, without lumps, was formed the remaining amount of water was added on cold and mixing
was continued till smooth homogenous gel is formed. Leaving the gel overnight in the refrigerator may be
necessary for complete gel dispersion.
Preparation of Carbopol 934 Gels:
Gels were prepared by dispersing 1% w/w Carbopol 934 in distilled water , being kept under mechanical
stirring at high speed. The dispersion was then neutralized (pH 7.4) by addition of 1% w/w triethanolamine.
Any entrapped air in the gel was allowed to escape by allowing the gels to stand overnight.
In Vitro Release Studies:
The dissolution test was performed using standard USP apparatus II with some modifications (Marzouk,
1999) by using modified paddle over watch glass using buffer solution of pH 7.4. The dissolution medium was
300 ml phosphate buffer pH 7.4. The temperature was maintained at 37 ± 0.5°C. The rotation speed was 50
rpm. Samples of 5ml was withdrawn at predetermined time intervals 5, 10, 30, 40, 45, 50, 60 minutes for gel
containing polymer concentration 2% w/w and 5, 10, 30, 40, 45, 60 ,90,120,150,180 minutes for gel
containing polymer concentration 4,6% w/w and replaced with fresh and preheated at 37±0.5°C buffer solution
each time. Samples were measured spectrophotometrically at 272 nm. All experiments were performed in
triplicate (n = 3). The amount released was calculated from the regression line of the standard curve developed
in the same medium. All naproxen gel formulae were subjected to kinetic analysis by fitting the release data
to different kinetic models to explain the release kinetics of naproxen from various gel preparations.
Curve fitting:
Curve fitting was performed using Microsoft Excel 2003 version. The dissolution data were fitted to
equation. Release exponent “n” was calculated The dissolution data were fitted to the following equation (Eq.
(1) (Kormeyer et al., 1983; Peppas, 1985; Ritger and Peppas, 1987a,b):
Mt ' M4 = kt n ----------------Eq.1
W here Mt/M4 is the fraction of drug released at time t, k is the kinetic constant of the system, and n is the
exponent characteristic of the mode transport (T able 2). The release exponent takes various values depending
upon different geometries (Ritger and Peppas, 1987b).
Table 1: com position of naproxen gels (% w/w).
Gel form ing agent
Gel form ing agent wt

Carb.
Pect.
Pect.
Pect.
H Phv
H Phv
H Phv
H Plv
H Plv
H Plv
CM C
CM C
CM C

2
2
4
6
2
4
6
2
4
6
2
4
6

PE wt
-----------------------------------IPM
N aLS
5/10
5/10
5/10
5/10
-----5/10
5/10
----5/10
5/10
----5/10
5/10
-----

N ap.wt

D ist.W ater

1
1
1
1
1
1
1
1
1
1
1
1
1

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad

100
100
100
100
100
100
100
100
100
100
100
100
100

g
g
g
g
g
g
g
g
g
g
g
g
g

PE; penetration enhancer; IPM;isopropyl myristate; NaLS;sodium lauryl sulphate
Nap; naproxen; Pect; pectin; Carb; carbopol 934; CMC; carboxy methyl cellulose
HPhv;hydroxyl propyl methyl cellulose viscosity 15000; HPlv; hydroxyl propyl methyl cellulose viscosity 4000
Table 2: Transport M echanism s from a polym er tablets U nder Sink Conditions
D iffusional release exponent (n)
O verall solute diffusion m echanism
0.5
Fickian diffusion (Higuchi release)
0.5 < n < 1.0
N on-Fickian (anom alous)
1.0
Tim e-independent linear transport (Zero-order release)
n >1.0
Super Case II Transport
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In Vitro Perm eation Studies Through Rat Skin.
Skin Membrane Preparation:
The abdominal hair of wistar male rats, weighing 160 ±25 g, was shaved using electric and hand razors.
After anesthetizing the rat with ether, the abdominal skin was surgically removed from the animal, and
adhering subcutaneous fat was carefully cleaned. To remove extraneous debris and leachable enzymes, the
dermal side of the skin was in contact with a saline solution for 1 hr before starting the diffusion experiment.
Perm eation Studies:
The rate and extent of skin permeation of naproxen sodium from gel formulations that showed the best
dissolution profile (gel prepared with 2% w/w gel forming agent with and without penetration enhancers) were
determined using a modified glass diffusion cell fitted with excised rat skin (Hsu et al., 1994). The skin was
mounted on the receptor compartment with the stratum corneum side facing upwards into the donor
compartment and the dermal side facing downwards into the receptor compartment. The donor cell was filled
with 1 g of 1% naproxen sodium gel with and without various types and concentration of penetration enhancers
and occluded by paraffin. The receptor compartment was filled with 50 ml of pH 7.4 phosphate buffer and
its temperature was maintained at 37±0.5 °C. The effective diffusion area was 4.9 cm 2 . Approximately 3 ml
of the receptor medium was withdrawn at determined intervals and replaced immediately with an equal volume
of receptor solution to maintain a constant volume. The sample withdrawn from the receptor compartment was
then analyzed spectrophotometrically at ëmax 272 nm. Each data point represents the average of three
determinations.
Data Treatment:
In vitro, the cumulative amount of the drug penetration through rat skin was plotted as a function of time
and a linear regression analysis was used to determine the flux and lag time of the drug. The effectiveness
of penetration enhancers can be determined by penetration index (PI) which is expressed as PI=flux of drug
with enhancers/ flux of drug without enhancers (W u et al., 1996).
The skin flux was determined from Fick’s law of diffusion:
Js = dQr/Adt --------------------Eq.2
W here Js is the steady-state skin flux in μg/cm 2 /h, dQr is the change in quantity of the drug passing through
the skin into the receptor compartment in μg, A is the active diffusion area in cm 2 , and dt is the change in
time. The flux was calculated from the slope of the linear portion of the profiles.
The lag-time was determined by extrapolating the linear portion of the curve to the abscissa (Niazy, 1996).
The permeability coefficient (P) was calculated as (Scheuplein, 1978)
P = Js/Cs ------------------------Eq.3
W here Cs is the saturated solubility of drugs in donor solutions.
Statistical analysis was carried out using analysis of variance (ANOVA), the level of significance was
taken as P < 0.05. A correlation analysis was performed with the help of the Instate program, and correlation
coefficients were examined for significance (P < 0.05) using Tukey (post test) for multiple comparison.
Duration of Antiinflam m atory Activity of Naproxen Gel:
Schier et al. (1986) studied the duration of antiinflammatory action of meclofenamic acid and indomethacin
topical formulations in mice. This method was not suitable for evaluating the antiinflammatory activity of a
drug for >10 hr due to the limited duration of the inflammatory response after carrageenan injection in mice.
Another method has been suggested by Chi et al., 1990 for the determination of duration of antiinflammatory
activity in rats, wherein the extended duration of antiinflammatory activity of the new gel formulation of
naproxen sodium was measured by applying the gel to the paw much earlier than the carrageenan injection.
Six groups, each containing six rats, were selected and 0.5 g of 1% naproxen sodium in pectin gel without
enhancer was applied on the plantar region of their left hind paw at 0, 1, 2, 3, 4, 6, 8, 12, 24 and 30 hr prior
to the injection of 0.1 ml of the 1% carrageenan solution. Three hours after the carrageenan injection, the
percent swelling of the paw was measured in each rat, and the average percent inhibition of oedema formation
at each dosing interval was calculated using Eq. 4
Percent inhibition = [1-percent swelling of drug-treated group/percent swelling of control group]
×100. -------------------------Eq.4
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Six rats were used as control animals, and they received the gel base alone 3 hr prior to the injection of
carrageenan.
Pharm acokinetics Study of Naproxen Sodium Gel:
Protocol:
The gel formulation that gave best in vitro permeation flux through rat skin (1% naproxen sodium in 2%
pectin gel) was subjected to in vivo study. Furthermore the effect of gel forming agent type (1% naproxen
sodium in HPlv gel and carbopol gel) on transdermal absorption of drug through human skin was evaluated.
Also one marketed product, naprofen® 250 mg tablet (El-Nile Pharmaceutical Co., Egypt) was orally
administered to six healthy human male volunteers in order to identify the pharmacokinetic properties and
relative bioavailability of naproxen sodium for all the formulations.
In vivo experiments were carried out on six human volunteers of healthy Egyptian male in the age range
25–35 years. The volunteers were fully informed of the nature of the study and the procedures involved. The
participants did not suffer from any disease and were not on any medication at the time of the study. On the
first day of the study, immediately, after taken the initial blood sample, 1 g gel was applied to the skin on
the ventral surface of the forearm, and was rubbed in for 1 minute, over an area approximately 5x 20 cm 2 .
Heparinized venous blood samples were drawn just before administration and at 0.5, 1, 2, 3, 4, 6, 8, 12,
24, 48 and 72 hr postdose. Plasma was separated and frozen prior to assay for naproxen sodium by HPLC.
All volunteers fasted until 3 h after drug administration. A 15-day washout period was left between the dosing
days.
Drug Analysis:
Naproxen sodium (determined as naproxen ;i.e., the free-acidic form of the naproxen sodium salt) plasma
level was simultaneously determined by using an HPLC method developed and validated by personnel of
Fundacion A.C., Liomont, Mexico City, Mexico (Jose Antonio et al., 2009) with slight modification in which
propylparaben sodium( El-Nasr Pharmaceutical Co., Egypt) was used as the internal standard. The method
included 0.5 ml of plasma, 0.01 ml of internal standard (propylparaben sodium 20ìg/ml), and 0.5 ml ZnSO 4
0.014 M. These components were mixed together in a 2.0 ml conical tube and vortexes (Vortex mixer,
Medtronic, P-selecta, 246539, Switzerland) for 1 minute. The tube was cooled in a freezer (-75°C ± 5°C)(
General Electric, 500 P123, USA) for 1.5 minutes and then centrifuged at 1440g (Centrifuge Janetzki T30,
Germany) for 12 minutes at room temperature (25°C). The supernatant was separated and injected into the
chromatographic system (model HP1100, Hewlett-Packard, Les, Ulis, UK). Naproxen concentrations were
determined using analytical column LICHrospher100RP18(Sum Putielesize, 125 x 4 cm) and eluted with a
mobile phase consisting of a mixture (79.5:20.5 v/v) of an aqueous buffer solution (ammonium phosphate 5
mM; pH 6.0 ± 0.2) and acetonitrile. The column temperature was 25°C. Flow rate was maintained at 1.0
ml/min and naproxen was detected by a UV detector (Agilent Technologies) set at a wavelength of 230 nm.
Typical retention times for naproxen, and the internal standard were 9, and 2 minutes, respectively. Naproxen
peak areas were used for its quantification. Under these conditions, the method was linear in the range of 25
to 250 ng /ml (25, 50, 70, 90, 170, 245, and 250 ng /ml; lower limit of quantification =25 ng /ml) for
naproxen. Accuracy for naproxen was between 92.1% and 106.4%; the relative SD was always <7%.
Quality control (QC) samples were included in every analytical run (during both method validation and
analysis of the study samples) to verify performance.
Calculations of the Pharmacokinetic Param eters and Statistical Analyses:
AUC 0 -4 is the area under the plasma concentration vs. time curve, calculated using the trapezoidal rule for
the time interval 0 to the last measurable point, 72 h. The peak plasma concentration (C m ax ) and time to reach
the maximum drug plasma concentration (T m ax ) was determined from visual inspection of the concentration–time
plots. The relative bioavailability of topical naproxen gel formulations, compared to Naprofen® tablet, was
calculated according to the formula:
[AUC ] T
Relative bioavailability (%) = )))))) × 100
[AUC ] R
W here [AUC] R is the area under the curve of Naprofen® tablet, and [AUC]
topical naproxen gel formulations.
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Each experiment was repeated six times and the mean value with standard deviation was presented.
Student’s t-test was performed to see any significant difference in pharmacokinetic parameters between the
control and test preparations.
RESULTS AND DISCUSSION
In Vitro Release Studies:
Dissolution profiles of 1% naproxen sodium gel formulations prepared with 2, 4, and 6% polymer (pectin,
carbopol, CMC, HPhv and HPlv) without penetration enhancer are shown in Figs. (1, 2 and 3) respectively.
As shown in the figures the fastest release of naproxen sodium are shown from gel prepared with low % of
gel forming agent as 100% released of naproxen from HPlv is reached only after 10 minutes. W hile by using
more % of the same gel forming agent the % released of drug will be much delayed as it reached 95% after
3 hours with HPlv. The effect of addition various penetration enhancers with different ratio on the release of
naproxen sodium from gel formulations prepared with 2% of the five selected gel forming agent are shown
in Figs. (4-8). It is clear that the penetration enhancer IPM and NaLS delay the release of naproxen sodium
from most of gel formulations when used in both ratios (5 and 10% ).As 100% release of naproxen sodium was
showed after 45 minutes from gel formulation prepared with pectin and 5%IPM, while it reaches 100% after
only 20 minutes when used pectin base only without any penetration enhancers. On the contrary, the gel
formulation that prepared with 2% carbopol show slightly enhancing when used with 10% NaLS as 100%
naproxen sodium was released after one hour in contrast to 84% released from gel prepared with carbopol
only.
The release exponent (n) values varied from 0.0988 to 1.168 which indicates that drug release from the
prepared gel mostly follows a Fickian drug release pattern unless with few formulation shows super Case II
Transport and others show non-fickian drug release pattern. The correlation coefficient (R 2 ) values ranged from
1 to 0.9297. All the release kinetic parameters of naproxen sodium from the studied formulae are given in
Table (4).
In Vitro Perm eation Studies Through Rat Skin:
Aliphatic esters, such as IPM , have been reported to act as permeation enhancers (Sato et al., 1988; Ozawa
et al., 1988). Also, Na-laurylsulfate is surfactant has role as penetration enhancer (Junginger and Verhoef,
1998) .In order to evaluate the effect of IPM and NaLS on the percutaneous absorption of naproxen sodium,
experiments from gels containing the 5, 10% IPM were carried out. The diffusion experiments showed that
naproxen sodium is able to permeate abdominal rat skin from formulations prepared with 2% gel forming agent
of pectin, HP hv, HP lv and CMC and 2% carpopol without and with 5, 10% penetration enhancers IPM and
NaLS. The steady-state flux (J), permeability coefficients of the formulations and the penetration index (PI)
of each enhancer were calculated and listed in Table (4). These results demonstrate that 5, 10 % NaLS and
IPM were ineffective accelerant for the drug as naproxen sodium flux was markedly decreased from all
formulations. The most outstanding permeation showed with using pectin as gel forming agent without any
penetration enhancer as the naproxen sodium flux reaches 82 (μgcm -2 hr -1 ). W hereas the NaLS and IPM showed
mild accelerant activity with formulation that prepared using 2% carbopol as the naproxen sodium flux was
slightly increased to 14, 12 μgcm -2 hr -1 with 10% IPM and NaLS, respectively.
Duration of Antiinflam m atory Activity of Naproxen Sodium Gel:
Table (5) shows the percent inhibition of the oedema formation after the topical application of 1%
naproxen sodium gel prepared using 2% pectin and without penetration enhancer at various times between 0-30
hr prior to the carrageenan injection. W hen the gel was applied on the rat paw between 6 hr prior to the
carrageenan injection, the maximum inhibition was observed at 3 hr after the carrageenan injection (60.72%).
It is clear that the time required for maximum inhibition (T m ax)was observed at 6 hr prior carragenan injection
.W hen the gel was applied 12-30 hr prior to the carrageenan injection, gradually decreased in inhibition was
observed at 3 hr after the carrageenan injection (7.225% at 30 hr prior injection). These results clearly indicate
the prolonged antiinflammatory activity of 1% naproxen sodium gel prepared.
Pharmacokinetic Param eters:
The selection of an appropriate base is very important in increasing the efficacy of a topically applied
drug. Topical application of non-steroidal anti-inflammatory drugs such as naproxen is very useful for local
activity in various arthritic conditions which also avoids GI disturbances. Hence in the present study,
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percutaneous absorption of naproxen from pectin gel, carbopol gel, and HPlv gel was evaluated to assess the
effect of base on the absorption of naproxen. As the plasma concentration is the most important determinant
of the pharmacological effect, simultaneous estimation of plasma concentration of naproxen was undertaken
at the same time intervals at which the plasma concentration of naproxen sodium reference tablet Naorofen
® was estimated, in the same human volunteers.
Table 3: D issolution kinetic param eters of naproxen sodium from gel form ulations prepared with 2% different gel form ing agents
param eters
------------------------------------------------------------Gel form ing agent
Enhacer ratio
Release exponent
Correlationcoefficient
Kinetic constant
n
R2
K
2% H Phv
W ithout enhancer
0.3612
0.9994
0.3339
5% IPM
0.26461
0.95613
0.42629
10% IPM
0.1455
0.9016
0.50501
5% N aLS
0.1952
0.9986
0.51386
10% N aLS
0.1596
0.9607
0.59597
2% H Plv
W ithout enhancer
0.21996
1.0000
0.5965
5% IPM
0.3064
0.94078
0.3382
10% IPM
0.2929
0.9018
0.36263
5% N aLS
0.2668
0.9848
0.3531
10% N aLS
0.1458
0.9857
0.59959
2% Pectin
W ithout enhancer
0.6537
0.9431
0.1531
5% IPM
0.2788
0.99206
0.3432
10% IPM
0.5291
0.96939
0.1807
5% N aLS
0.2677
0.99
0.39837
10% N aLS
0.2824
0.9865
0.3611
2% CM C
W ithout enhancer
0.0988
0.9914
0.70183
5% IPM
0.2132
0.98054
0.4641
10% IPM
0.3352
0.9297
0.24198
5% N aLS
0.1669
0.9875
0.54329
10% N aLS
0.1175
0.9684
0.64957
2% Carbopol
W ithout enhancer
0.7436
0.99101
0.04463
5% IPM
0.5743
0.9936
0.08123
10% IPM
1.168
0.9649
0.00708
5% N aLS
0.56301
0.9968
0.08653
10% N aLS
0.3549
0.9708
0.21407
Table 4: Effect of gel form ing agent type and penetration enhancer on naproxen sodium skin perm eation param eters a .
Gel form ing agent
Enhancer ratio
Flux (μgcm -2 hr -1 )
P(cm hr -1 )
2% H Plv
W ithout enhancer
36 ± 1.1
0.0036
5% IPM
16±1.9
0.0016
10% IPM
10±2
0.001
5% N aLS
8±0.8
0.008
10% N aLS
10±1.3
0.001
2% H Phv
W ithout enhancer
30±1.1
0.003
5% IPM
31±0.56
0.0034
10% IPM
16±1.5
0.0016
5% N aLS
4±2.9
0.0004
10% N aLS
8±1.87
0.0008
2% Pectin
W ithout enhancer
82±3.4
0.0082
5% IPM
42±5
0.0042
10% IPM
18±2.4
0.0018
5% N aLS
12±2.2
0.0012
10% N aLS
14±2.9
0.0014
2% CM C
W ithout enhancer
30±4.3
0.003
5% IPM
10±3.1
0.001
10% IPM
10±2
0.001
5% N aLS
6±1.1
0.0006
10% N aLS
7±1
0.0007
2% Carbopol
W ithout enhancer
8±0.9
0.0008
5% IPM
10±2.2
0.001
10% IPM
14±3.2
0.004
5% N aLS
6±4
0.0006
10% N aLS
12±5.3
0.0012
a
Values are the m ean ± S.D . of three determ inations at 37°C ; PI; penetration index; P, perm eability coefficient.
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PI
-0.44
0.277
0.22
0.277
-1.1
0.5
0.13
0.26
-0.5
0.2
0.14
0.17
-0.33
0.33
0.2
0.23
-1.25
1.75
0.75
1.5
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Table 5: D uration of anti-inflam m atory effect of 1% naproxen sodium in pectin gel.
Tim e (hr)
Percent swelling
control
40 ± 3.1
0
35.62 ±1.75
1
30.512 ±.11
2
24.44 ±1.23
3
21.13 ±1.09
4
18.92 ±1.24
6
15.71 ±2.54
8
23 ±2.16
12
27.2 ±2.02
24
30.9 ±2.9
30
37.1 ±13.1

Percent inhibition
10.95
23.72
38.9
47.17
52.7
60.72
42.5
32
22.75
7.225

Fig. 1: Dissolution profile of 1% naproxen sodium from 2% different gel bases without enhancers.

Fig. 2: Dissolution profile of 1% naproxen sodium from 4% different gel bases without enhancers.

Fig. 3: Dissolution profile of 1% naproxen sodium from 6% different gel bases without enhancers
Mean plasma concentration-time curves of the 4 naproxen sodium formulations are depicted in Fig. (9)
and PK parameters (C m ax , T m ax , t1 /2 , and AUC 0 -4 ) are summarized in Table (6). The results clearly indicated
that the absorption profile of naproxen is better from pectin gel base when compared to that from the other
two bases. The drug plasma concentration obtained from pectin gel base was significantly (P < 0.001) higher
as compared to that from the other two bases at all time points (Fig. 9). The order of absorption based on the
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plasma concentration of naproxen from three different gel bases are as follows: pectin gel > HPlv gel >
carbopol gel. These findings were in accordance with the results of Sastry et al., 1995. After application of
1% naproxen sodium in pectin gel, the mean plasma naproxen concentration was found to exceed 0.1ìg/ml
after 3 hr, the highest mean concentration was1.27 ìg/ml at 6 hr with correlation with previous results obtained
from anti inflammatory duration study on rats and the mean plasma concentration 72 hr after application was
0.45ìg/ml. W hile after application of 1% naproxen sodium in HPlv gel, mean plasma naproxen concentration
was found to exceed 0.1ìg/ml after 1 hr, the highest mean concentration was 0.887 ìg/ml at 8 hr and the
mean plasma concentration 72 hr after application was 0.06ìg/ml. It is clear that after application of 1%
naproxen sodium in carbopol gel, a similar picture was found, mean plasma naproxen concentration was found
to exceed 0.1ìg/ml after 1 hr, the highest mean concentration was 0.786 ìg/ml at 6 hr and the mean plasma
concentration 72 hr after application was 0.039ìg/ml. In addition, Table (6) shows the bioavailability % (test
/reference) for tested formulations were ranged from 19.5 to 36.

Fig. 4: Dissolution profile of 1% naproxen sodium from 2% HPMC 4000 gels with and without different
penetration enhancers.

Fig. 5: Dissolution profile of 1% naproxen sodium from 2% CM C gels with and without different penetration
enhancers.

Fig. 6: Dissolution profile of 1% naproxen sodium from 2% Carbopol 934 gel with and without different
penetration enhancers.
Significant differences (P<0.001) were indicated for the area under the plasma–time curve (AUC)
parameter between all of the formulations. 1% naproxen sodium in pectin gel showed the highest bioavailability
followed by 1% naproxen sodium in HPlv gel, and 1% naproxen sodium in carbopol gel. Interestingly, the
estimated t 1 /2 of naproxen for all formulations was in the range of mean values from 5.035 to 8.08 hours
(Table 6). These values appeared to indicate a slightly shorter t1 /2 versus the reported naproxen (or naproxen
sodium) t 1 /2 which ranges from 12 to 17 hours (Jose Antonio et al., 2009).
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Fig. 7: Dissolution profile of 1% naproxen sodium from 2% HPhv gels with and without different penetration
enhancers.

Fig. 8: Dissolution profile of 1% naproxen sodium from 2% pectin gels with and without different penetration
enhancers.

Fig. 9: Mean plasma naproxen concentration-time curve for the test formulations (1% naproxen sodium in
pectin, HPlv and carbopol gel) and reference oral-tablet (Trademark Naprofen 250 mg El-Nile
Pharmaceutical Co., Egypt) Values are mean ( ± SD n = 6).
Table 6: Pharm acokinetic param eters of naproxen after adm inistration of oral reference tablet and three topical gel tests to hum an
volunteers.
nap formulation
Pharm acokinetic param eters
---------------------------------------------------------------------------------------------------------------------------------------t ½
C m ax
T m ax
AU C 0 -4
B ioavailbi
lity
h
ìg/m L
h
ìg/m L. h
%
Reference nap tablet
1.329
6
9.7416
10.9483
-1% nap pectin gel
1.276
6
8.0838
15.9441
36.4
1% nap HPlv gel
0.887
8
5.0375
14.4199
32.92
1% nap carbopol gel
0.786
6
5.7916
8.5782
19.588

Conclusion:
The experiments have demonstrated that the type of gel forming agent have great effect on the permeation
of naproxen sodium through human and rat skin. It is also obvious that the penetration enhancers NaLS and
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IPM when added clearly decreased the permeation of naproxen sodium across the skin in vitro and in vivo.
Hence topical application of naproxen in the pectin gel without penetration enhancers may be of potential use
for local and systemic activity and will also avoid GI disturbances.
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